Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directionsRiccardo Gerosa, Alberto Zambelli, Rita De Sanctis et al.|Critical Reviews in Oncology/Hematology|2024Cited by 87
Opportunities and Challenges of Synthetic Data Generation in OncologyFlavia Jacobs, Alberto Zambelli, Matteo Giovanni Della Porta et al.|JCO Clinical Cancer Informatics|2023Cited by 36
Hope and Hype around Immunotherapy in Triple-Negative Breast CancerFlavia Jacobs, Armando Santoro, Elisa Agostinetto et al.|Cancers|2023Cited by 20
HR+/HER2– de novo metastatic breast cancer: a true peculiar entity?Rosalba Torrisi, Armando Santoro, Flavia Jacobs et al.|Drugs in Context|2023Cited by 19
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast CancerGiuseppe Saltalamacchia, Alberto Zambelli, Rosalba Torrisi et al.|Biomedicines|2024Cited by 9